BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230711
DTEND;VALUE=DATE:20230714
DTSTAMP:20260516T064946
CREATED:20230302T092937Z
LAST-MODIFIED:20230302T092937Z
UID:36706-1689033600-1689292799@www.pharmajournalist.com
SUMMARY:2nd Digital Biomarkers & Clinical Measures in Neurology Summit
DESCRIPTION:CNS biopharma is rapidly investing in digital technologies to revolutionize clinical identification and monitoring of complex neurological disorders through more objective\, frequent\, sensitive\, and less invasive measures of movement\, speech\, and cognition. \nReturning to Boston\, the 2nd Digital Biomarkers & Clinical Measures in Neurology Summit is the only industry-specific meeting dedicated to developing translatable\, scalable\, and successful digital technologies and measures specifically to be incorporated into neurological clinical trials. \nThis is your must-attend meeting tackling the development of digital measures to revolutionize clinical assessments across neurological drug development. \nUniting Digital Health Biopharma with CNS Clinical Drug Developers to: \n\nAddress the Standardization & Regulatory Acceptance of Digital Tools & Data Analysis as Endpoints in Complex Neurological Indications\nDiscover Novel Innovations for Objective\, Sensitive\, & Non-Invasive Neurological Measures\nEnsure Confidence & Scalability with Emerging Digital Technologies\n\nTo know more visit: https://ter.li/nx0m2f
URL:https://www.pharmajournalist.com/event/2nd-digital-biomarkers-clinical-measures-in-neurology-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230711
DTEND;VALUE=DATE:20230714
DTSTAMP:20260516T064946
CREATED:20230405T231354Z
LAST-MODIFIED:20230405T231354Z
UID:37027-1689033600-1689292799@www.pharmajournalist.com
SUMMARY:2nd Annual Optimizing AAV Safety Summit 2023
DESCRIPTION:With more than 300 trials in preclinical and clinical development actively using AAV as their vector of choice\, the priority for any company working in this space is to ensure that each and every one of those therapies is the safest version it can be. \nIn this context\, the 2nd Annual Optimizing AAV Safety Summit is returning in 2023\, bringing together genetic therapy leaders across non-clinical development\, clinical development\, toxicology\, biodistribution\, and immunology who are all working to optimize the safety of their AAV-based drug products in their day-to-day. \nBy addressing key topics including how to extract the most relevant data from preclinical studies to better inform how humans will respond to an AAV-based therapy in the clinic\, analyzing potential integration risks of AAV serotypes\, and investigating regulatory approaches to safety packages for submission\, this meeting will inform how to streamline AAV safety processes to de-risk delays and shorten timelines to approval. \nJoin us in Boston to be part of the solution to bringing safer\, effective genetic therapies to patients and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development. \nTo know more visit: https://ter.li/6gzgy4
URL:https://www.pharmajournalist.com/event/2nd-annual-optimizing-aav-safety-summit-2023/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR